senp1 in 1

SENP1-IN-1 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

Vialinin A (Terrestrin A), a p-terphenyl compound, exhibits antioxidant properties and acts as a potent inhibitor of TNF-α, USP4, USP5, and sentrin SUMO-specific protease 1 (SENP1). Its efficacy in autoimmune diseases and cancer research is noteworthy, highlighting its potential therapeutic applications.

SENP1-IN-3 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

SENP1-IN-4, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

SENP1-IN-2, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

Hinokiflavone, a novel modulator of pre-mRNA splicing activity both in vitro and in cellulo, inhibits the assembly of the spliceosome, particularly blocking the formation of the B complex. Additionally, it acts as a SUMO protease inhibitor by impeding the activity of sentrin-specific protease 1 (SENP1). Hinokiflavone also demonstrates significant cytotoxicity, including the inhibition of MMP-9.

SENP2-IN-1 is a selective inhibitor of SENP2. SENP2-IN-1 inhibits SENP1 (IC50: 1.3 μM), SENP2 (IC50: 0.69 μM) and SENP5 (IC50: 22.7 μM). SENP2-IN-1 can be used in cancer research.